title: Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab.
abstract: OBJECTIVE
  To report a rare case of central vision loss in a patient with choroideremia.
  
  
  METHODS
  A retrospective, interventional case report.
  
  
  RESULTS
  A 13-year-old male with history of choroideremia presented with subacute loss of central acuity in his left eye. Examination and diagnostic testing revealed subretinal fibrosis secondary to a choroidal neovascular membrane (CNVM). A trial of anti-vascular endothelial growth factor (VEGF) therapy with the injection of intravitreal bevacizumab was attempted. Mild improvements in acuity and anatomy were noted.
  
  
  CONCLUSIONS
  Choroideremia is a rare hereditary choroidal dystrophy that predominantly affects males in the first and second decades of life. Visual acuity is usually spared until later in life. CNVM is a rare manifestation of choroideremia with only a handful of case reports presented in the literature. This case is unique in that it is the first reported case that received treatment with intravitreal anti-VEGF therapy.
authors.affiliation: Oregon Retinal Degeneration Center (ORDC), Ophthalmic Genetics Service and Retina-Vitreous Service, Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Neal V
authors.initials: NV
authors.lastname: Palejwala
authors.affiliation: Oregon Retinal Degeneration Center (ORDC), Ophthalmic Genetics Service and Retina-Vitreous Service, Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Andreas K
authors.initials: AK
authors.lastname: Lauer
authors.affiliation: Oregon Retinal Degeneration Center (ORDC), Ophthalmic Genetics Service and Retina-Vitreous Service, Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA.
authors.forename: Richard G
authors.initials: RG
authors.lastname: Weleber
keywords: anti-VEGF therapy; chorioretinal degeneration; choroidal neovascular membrane; choroideremia; hereditary choroidal dystrophy; intravitreal bevacizumab injection